Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GXO Logistics IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Regeneron Pharmaceuticals Inc — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Regeneron Pharmaceuticals Inc trades at $678.67 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.6× GXO Logistics Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.

GXOREGN
Market Cap
$6.02B$69.66B
Sector
IndustrialsHealth
52-Week High
$65.59$812.27
52-Week Low
$45.52$542.52
Enterprise Value
$11.18B$63.61B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.

GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.

Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN